Unknown

Dataset Information

0

Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.


ABSTRACT: Our previous study showed that prostate cancer cells overexpress and secrete secretory phospholipases A2 group IIa (sPLA2-IIa) and plasma sPLA2-IIa was elevated in prostate cancer patients. The current study further explored the underlying mechanism of sPLA2-IIa overexpression and the potential role of sPLA2-IIa as a prostate cancer biomarker.Plasma and tissue specimens from prostate cancer patients were analyzed for sPLA2-IIa levels. Regulation of sPLA2-IIa expression by Heregulin-? was determined by Western blot and reporter assay.We found that Heregulin-? enhanced expression of the sPLA2-IIa gene via the HER2/HER3-elicited pathway. The EGFR/HER2 dual inhibitor Lapatinib and the NF-kB inhibitor Bortezomib inhibited sPLA2-IIa expression induced by Heregulin-?. Heregulin-? upregulated expression of the sPLA2-IIa gene at the transcriptional level. We further confirmed that plasma sPLA2-IIa secreted by mouse bearing human prostate cancer xenografts reached detectable plasma concentrations. A receiver operating characteristic (ROC) analysis of patient plasma specimens revealed that high levels of plasma sPLA2-IIa, with the optimum cutoff value of 2.0 ng/ml, were significantly associated with high Gleason score (8-10) relative to intermediate Gleason score (6-7) prostate cancers and advanced relative to indolent cancers. The area under the ROC curve (area under curve, AUC) was 0.73 and 0.74, respectively.We found that Heregulin-?, in addition to EGF, contributes to sPLA2-IIa overexpression in prostate cancer cells. Our findings support the notion that high levels of plasma sPLA2-IIa may serve as a poor prognostic biomarker capable of distinguishing aggressive from indolent prostate cancers, which may improve decision-making and optimize patient management.

SUBMITTER: Oleksowicz L 

PROVIDER: S-EPMC3345320 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.

Oleksowicz Leslie L   Liu Yin Y   Bracken R Bruce RB   Gaitonde Krishnanath K   Burke Barbara B   Succop Paul P   Levin Linda L   Dong Zhongyun Z   Lu Shan S  

The Prostate 20111129 10


<h4>Background</h4>Our previous study showed that prostate cancer cells overexpress and secrete secretory phospholipases A2 group IIa (sPLA2-IIa) and plasma sPLA2-IIa was elevated in prostate cancer patients. The current study further explored the underlying mechanism of sPLA2-IIa overexpression and the potential role of sPLA2-IIa as a prostate cancer biomarker.<h4>Methods</h4>Plasma and tissue specimens from prostate cancer patients were analyzed for sPLA2-IIa levels. Regulation of sPLA2-IIa ex  ...[more]

Similar Datasets

| S-EPMC3250967 | biostudies-literature
| S-EPMC3412631 | biostudies-literature
| S-EPMC2981059 | biostudies-literature
| S-EPMC5495423 | biostudies-literature
| S-EPMC7288094 | biostudies-literature
| S-EPMC1222685 | biostudies-other
| S-EPMC5599634 | biostudies-literature
| S-EPMC2578825 | biostudies-literature
| S-EPMC10778238 | biostudies-literature
| S-EPMC6557629 | biostudies-literature